CY1108863T1 - Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη - Google Patents

Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη

Info

Publication number
CY1108863T1
CY1108863T1 CY20091100254T CY091100254T CY1108863T1 CY 1108863 T1 CY1108863 T1 CY 1108863T1 CY 20091100254 T CY20091100254 T CY 20091100254T CY 091100254 T CY091100254 T CY 091100254T CY 1108863 T1 CY1108863 T1 CY 1108863T1
Authority
CY
Cyprus
Prior art keywords
weight percent
tablet
pharmaceutical preparation
independent release
water
Prior art date
Application number
CY20091100254T
Other languages
Greek (el)
English (en)
Inventor
Kevin R Engh
Yihong Qiu
Venkatramana Rao
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1108863T1 publication Critical patent/CY1108863T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20091100254T 1999-02-04 2009-03-06 Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη CY1108863T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24467899A 1999-02-04 1999-02-04
EP00904586A EP1146864B1 (en) 1999-02-04 2000-01-26 Ph independent extended release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
CY1108863T1 true CY1108863T1 (el) 2014-07-02

Family

ID=22923698

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100254T CY1108863T1 (el) 1999-02-04 2009-03-06 Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη

Country Status (10)

Country Link
EP (1) EP1146864B1 (cg-RX-API-DMAC7.html)
JP (2) JP5420126B2 (cg-RX-API-DMAC7.html)
AT (1) ATE424191T1 (cg-RX-API-DMAC7.html)
CA (1) CA2361496C (cg-RX-API-DMAC7.html)
CY (1) CY1108863T1 (cg-RX-API-DMAC7.html)
DE (1) DE60041691D1 (cg-RX-API-DMAC7.html)
DK (1) DK1146864T3 (cg-RX-API-DMAC7.html)
ES (1) ES2321908T3 (cg-RX-API-DMAC7.html)
PT (1) PT1146864E (cg-RX-API-DMAC7.html)
WO (1) WO2000045793A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US20020025341A1 (en) * 1998-12-18 2002-02-28 Yihong Qiu Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2002051402A1 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US20040175423A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
MX2011011459A (es) * 2009-04-29 2011-11-18 Rexahn Pharmaceuticals Inc Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
CN107811985B (zh) * 2016-09-13 2021-05-28 四川科瑞德制药股份有限公司 一种抗癫痫缓释制剂及其制备方法与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3809764A1 (de) * 1988-03-23 1989-10-05 Knoll Ag Mischung aus alginaten und polyacrylaten und deren verwendung
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
DE69617245T2 (de) * 1995-08-17 2002-07-25 Csir, Pretoria Produkte mit gesteuerter freisetzung
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
DK0921793T3 (da) * 1997-03-11 2000-12-18 Hexal Ag Faste, ikke-henflydende formuleringer af natriumvalproat

Also Published As

Publication number Publication date
DK1146864T3 (da) 2009-05-11
JP2011241218A (ja) 2011-12-01
ES2321908T3 (es) 2009-06-15
DE60041691D1 (de) 2009-04-16
ATE424191T1 (de) 2009-03-15
EP1146864B1 (en) 2009-03-04
WO2000045793A1 (en) 2000-08-10
PT1146864E (pt) 2009-03-20
JP2002536318A (ja) 2002-10-29
CA2361496C (en) 2011-06-07
JP5420126B2 (ja) 2014-02-19
JP5420590B2 (ja) 2014-02-19
CA2361496A1 (en) 2000-08-10
EP1146864A1 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
CY1108863T1 (el) Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη
CA2318128C (en) Oral liquid compositions
HUP9800516A2 (hu) Gyógyszerforma kevéssé oldódó, bázisos gyógyszerhatóanyagok szabályzott felszabadítására
EP0136103B1 (en) Amosulalol hydrochloride long acting formulations
KR20030013460A (ko) 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
ATE217188T1 (de) Granulierte pharmazeutische zusammensetzung
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
CA2352211A1 (en) Sustained release matrix systems for highly soluble drugs
EP0966966A3 (en) Nefazodone dosage form
JPS6388122A (ja) 吸収および作用が速やかなサリンダツクまたはサリンダツクナトリウムと塩基の併用剤
BR0212155A (pt) Composição farmacêutica
US4738850A (en) Controlled release formulation and method
SE9603480L (sv) Beredningsform för svårlösliga läkemedel
ES2186207T3 (es) Metodo para preparacion de formulaciones farmaceuticas.
KR100815040B1 (ko) 비스포스포네이트계 약물의 경구흡수 개선을 위한약제학적 조성물
WO2005041876A3 (en) Spill resistant formulations containing clays
IT1303753B1 (it) Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
EP0121901B1 (en) Ph independent controlled releasable tablets
JP2005075831A (ja) 普遍的な放出制御組成物
WO1999001120A1 (en) Solubilized sertraline compositions
Widaa et al. Formulation and Characterization of Sodium Valproate 200mg Enteric Coated Tablets
TH51543A3 (th) รูปแบบยาของเนฟาโซโดน